Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study

Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study

Abstract Background Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not known. Methods EORTC-2227-BTG (LEGATO, NCT05904119) is an investigator-initiated, pragmatic (PRECIS-2 sc...

Full description

Bibliographic Details
Main Authors: Matthias Preusser, Tomáš Kazda, Emilie Le Rhun, Felix Sahm, Marion Smits, Jens Gempt, Johan AF Koekkoek, Angelo F Monti, Marcell Csanadi, János György Pitter, Helen Bulbek, Beatrice Fournier, Caroline Quoilin, Thierry Gorlia, Michael Weller, Giuseppe Minniti, on behalf of the European Organisation for Research, Treatment of Cancer (EORTC) Brain Tumor Group
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Trials
Subjects:
Glioblastoma
Progression
Lomustine
Reirradiation
LEGATO
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-024-08213-7

Internet

https://doi.org/10.1186/s13063-024-08213-7

Similar Items